Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial
European Journal of Cancer · 2025-10 · 228 · 115717
DOI: 10.1016/j.ejca.2025.115717 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2025-10. Verfasst von Yuan He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. University of Science and Technology…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. University of Science and Technology of China, Hefei, Anhui 230001, China; Core Facility Center, The First…
- Department of Pathology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. University of Science and Technology of China, Hefei, Anhui 230001, China.
- Department of Thoracic surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. University of Science and Technology of China, Hefei, Anhui 230001, China.
- Department of Thoracic surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. University of Science and Technology of China, Hefei, Anhui 230001, China. Electronic address: tjyong77@sina…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
He, Y., Liu, H., Li, X., Wang, J., Wu, H., Zhou, H., Wang, X., Cheng, J., Ma, J., Mei, X., Tian, J., & Qian, D. (2025). Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial. European Journal of Cancer, 228, 115717. https://doi.org/10.1016/j.ejca.2025.115717
Vancouver
He Y, Liu H, Li X, Wang J, Wu H, Zhou H, et al. Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial. European Journal of Cancer. 2025;228:115717. doi:10.1016/j.ejca.2025.115717
BibTeX
@article{He2025,
author = {He, Yuan and Liu, Huiquan and Li, Xiaoyang and Wang, Jianguo and Wu, Haibo and Zhou, Hangcheng and Wang, Xueru and Cheng, Jingjing and Ma, Jun and Mei, Xinyu and Tian, Jieyong and Qian, Dong},
title = {Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial},
journal = {European Journal of Cancer},
year = {2025},
volume = {228},
pages = {115717},
doi = {10.1016/j.ejca.2025.115717}
}
EUVIMED